Unpacking the Latest Options Trading Trends in Amgen
Unpacking the Latest Options Trading Trends in Amgen
Deep-pocketed investors have adopted a bearish approach towards Amgen (NASDAQ:AMGN), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AMGN usually suggests something big is about to happen.
资金雄厚的投资者们对安进（纳斯达克：AMGN）采取了看淡的策略，市场参与者不应忽视这一点。本周财经网站Benzinga对公开期权记录的追踪揭示了这一重大举措。这些投资者的身份仍然是未知的，但在AMGN中出现这样大规模的举动通常意味着即将发生重大事件。
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Amgen. This level of activity is out of the ordinary.
我们从观察当天的Benzinga期权扫描器中，发现了8个Amgen额外的期权活动，从而获得了这些信息。这种活动水平是不寻常的。
The general mood among these heavyweight investors is divided, with 37% leaning bullish and 62% bearish. Among these notable options, 6 are puts, totaling $287,160, and 2 are calls, amounting to $67,000.
这些重量级投资者中存在着两派对情绪，37%看好而62%看淡。在这些重要的期权中，有6个看跌期权，总价值为287160美元，2个看涨期权，总价值为67000美元。
Projected Price Targets
预计价格目标
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $315.0 and $355.0 for Amgen, spanning the last three months.
在评估交易量和未平仓量后，很明显主要的市场参与者正在关注安进的价格区间，这个区间位于315美元和355美元之间，跨度为过去三个月。
Volume & Open Interest Trends
成交量和未平仓量趋势
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
这些数据可以帮助您跟踪Coinbase Glb期权的流动性和利益，以给定的行权价格为基础。
This data can help you track the liquidity and interest for Amgen's options for a given strike price.
这些数据可以帮助您跟踪给定行权价格的安进期权的流动性和兴趣。
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Amgen's whale activity within a strike price range from $315.0 to $355.0 in the last 30 days.
下面我们可以观察到在过去30天，所有安进鲸鱼活动中，成交价在315美元到355美元之间的看跌期权和看涨期权的成交量和未平仓量的变化。
Amgen Option Activity Analysis: Last 30 Days
安进期权活动分析：最近30天
Noteworthy Options Activity:
值得注意的期权活动：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | PUT | SWEEP | BEARISH | 10/18/24 | $12.5 | $12.4 | $12.5 | $325.00 | $67.4K | 789 | 98 |
| AMGN | PUT | TRADE | BEARISH | 01/16/26 | $31.75 | $30.3 | $31.75 | $320.00 | $63.5K | 162 | 25 |
| AMGN | PUT | TRADE | BEARISH | 03/21/25 | $30.55 | $30.5 | $30.55 | $340.00 | $61.1K | 2 | 20 |
| AMGN | PUT | TRADE | BEARISH | 10/18/24 | $14.45 | $14.45 | $14.45 | $330.00 | $36.1K | 253 | 50 |
| AMGN | CALL | SWEEP | BULLISH | 08/09/24 | $3.45 | $2.57 | $3.45 | $355.00 | $34.5K | 16 | 100 |
| 标的 | 看跌/看涨 | 交易类型 | 情绪 | 到期日 | 卖盘 | 买盘 | 价格 | 执行价格 | 总交易价格 | 未平仓合约数量 | 成交量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | 看跌 | SWEEP | 看淡 | 10/18/24 | $12.5 | $12.4 | $12.5 | $325.00 | $67.4K | 789 | 98 |
| AMGN | 看跌 | 交易 | 看淡 | 01/16/26 | $31.75 | $30.3 | $31.75 | $320.00 | $63.5K | 162 | 25 |
| AMGN | 看跌 | 交易 | 看淡 | 03/21/25 | $30.55 | $30.5 | $30.55 | $340.00 | $61.1K | 2 | 20 |
| AMGN | 看跌 | 交易 | 看淡 | 10/18/24 | $14.45 | $14.45 | $14.45 | $330.00 | $36.1K | 253 | 50 |
| AMGN | 看涨 | SWEEP | 看好 | 08/09/24 | $3.45 | $2.57 | $3.45 | $355.00 | $34.5K | 16 | 100 |
About Amgen
关于安进
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
安进是生物技术制药领域的领导者。旗舰药物包括增加红细胞计数的艾普毕与阿拉尼许、增强免疫系统的奈帕姆和奈乌细胞移植因子、以及针对炎症性疾病的恩布瑞尔和欧特兹拉。安进在2006年推出了首个癌症治疗药物Vectibix，并推出了增强骨密度的药物Prolia/Xgeva（于2010年获批）和Evenity（于2019年获批）。对Onyx的收购增强了该公司在治疗肿瘤领域的药物组合，其中包括Kyprolis。最近推出的药物包括Repatha（降低胆固醇）、Aimovig（缓解偏头痛）、Lumakras（治疗肺癌）以及Tezspire（治疗哮喘）。2023年Horizon收购带来了几种罕见疾病药物，其中包括治疗甲状腺眼病的Tepezza。安进还拥有不断增长的生物类似物组合。
Current Position of Amgen
安进的当前位置
- Currently trading with a volume of 164,369, the AMGN's price is down by -0.04%, now at $334.17.
- RSI readings suggest the stock is currently may be overbought.
- Anticipated earnings release is in 11 days.
- 目前交易量为164,569股，AMGN的价格下跌了-0.04%，现价为334.17美元。
- RSI读数表明股票目前可能超买。
- 预期利润发布时间为11天后。
Expert Opinions on Amgen
安进的专家意见
2 market experts have recently issued ratings for this stock, with a consensus target price of $321.5.
两名市场专家最近对这只股票发表了评级，共识目标价格为321.5美元。
- An analyst from Argus Research has decided to maintain their Buy rating on Amgen, which currently sits at a price target of $340.
- An analyst from Morgan Stanley has decided to maintain their Equal-Weight rating on Amgen, which currently sits at a price target of $303.
- 雅运股份的一位分析师决定维持安进的买入评级，目标价为340美元。
- 大摩资源lof的一位分析师决定维持安进的等权重评级，目标价为303美元。
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
期权与仅交易股票相比是一种更具风险的资产，但它们具有更高的利润潜力。认真的期权交易者通过每日学习，进出交易，跟随多个指标并密切关注市场来管理这种风险。